ethnopharmacology-2017-scientifictracks-abstracts

13 / 25

Page 49
Notes:
conferenceseries.com
Volume 7, Issue 2 (Suppl) Clin Exp Pharmaco
ISSN: 2161-1459 CPECR, an open access journal Ethnopharmacology 2017
March 23-25, 2017
March 23-25, 2017 Orlando, USA
5th International Conference and Exhibition on
Pharmacology and Ethnopharmacology
Citrus oil and Dead Sea magnesium salts as antibacterial and anti-inflammatory agents
Boaz Mizrahi
Technion-Israel Institute of Technology, Israel
The antibacterial and anti-inflammatory properties of Dead Sea Magnesium Chloride (MgCl2), citrus oil and their combination
were investigated in this study. This combination is frequently used in several cultures to treat several gum diseases including
periodontitis and mouth sores. Citrus oil is composed of monoterpenes, in particular D-limonene, which is known to inhibit growth
of bacteria, fungi, and certain parasites. Inhibition of porphyromonas gingivalis in vitro was used to evaluate the antibacterial effect
of a mixture of Dead Sea magnesium chloride and citrus oil and of each of the components. A subcutaneous chamber model in mice
was used to assess the anti-inflammatory effect of the mixture and the individual components. Leukocyte migration, Tumor Necrosis
Factor-Alpha (TNF-a) secretion, and interleukin (IL)-10 secretion were determined. Hydrocortisone was used as a positive control.
Citrus oil had an antibacterial effect with a Minimal Inhibitory Concentration (MIC) of 1 mg/ml, whereas MgCl2 at concentrations up
to 10 mg/ml did not exhibit any antibacterial activity. However, a mixture of 10 mg/ml MgCl2 and 0.25 mg/ml citrus oil dramatically
increased inhibition of bacterial growth. The combination of MgCl2 and the citrus oil resulted in lower levels of TNF-a, and leukocyte
migration while maintaining the levels of IL-10 compared to the control. These findings suggest that a mixture of citrus oil and MgCl2
could be used as a natural antibacterial and anti-inflammatory agent.
Biography
Boaz Mizrahi has more than 10 years of experience in Biotechnology and Pharmaceutics, and he is the author of more than 20 scientific publications in this field.
Boaz gained his PhD degree in the group of Prof. Avi Domb at the Hebrew University, where he acquired first-hand experience in the engineering and synthesis
of materials for medical uses. He joined the Robert Langer Lab at MIT and the Daniel Kohane lab at Harvard Medical School. His research interest is focused on
understanding and mimicking principles that nature uses and on designing functional materials based on these concepts. He is the Co-inventor of 12 patents, 3 of
which were licensed.
Boaz Mizrahi, Clin Exp Pharmacol 2017, 7:2 (Suppl)